Evidence map›Paper›PMID 29145814›Full record

ArticleBMC cardiovascular disorders2017

Elevated exhaled acetone concentration in stage C heart failure patients with diabetes mellitus.

Tetsuro Yokokawa, Takamasa Sato, Satoshi Suzuki, Masayoshi Oikawa, Akiomi Yoshihisa, Atsushi Kobayashi, Takayoshi Yamaki, Hiroyuki Kunii, Kazuhiko Nakazato, Hitoshi Suzuki and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC cardiovascular disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. SGLT2 Inhibitors and Ketone Metabolism in Heart Failure.Journal of lipid and atherosclerosis · 2022
    Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Tetsuro YokokawaDepartment of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan. yokotetu@fmu.ac.jp.ORCID http://orcid.org/0000-0001-8197-3274
Takamasa SatoDepartment of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Satoshi SuzukiDepartment of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Masayoshi OikawaDepartment of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Akiomi YoshihisaDepartment of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Atsushi KobayashiDepartment of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Takayoshi YamakiDepartment of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Hiroyuki KuniiDepartment of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Kazuhiko NakazatoDepartment of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Hitoshi SuzukiDepartment of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Shu-Ichi SaitohDepartment of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Takafumi IshidaDepartment of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Akito ShimouchiDepartment of Lifelong Sports for Health Biochemical Sciences, College of Life and Health Sciences, Chubu University, Kasugai, Aichi, Japan.
Yasuchika TakeishiDepartment of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Fukushima Medical University · JPChubu University · JP

Funding

the Japanese Society for the Promotion of Science Kakenhi Grant 15K19401
6 · The paper itself

Abstract

backgroundBreath acetone is a noninvasive biomarker of heart failure; however, its significance in heart failure patients with diabetes mellitus has yet to be clarified. The objective of this study is to investigate whether exhaled acetone concentration is a noninvasive biomarker in heart failure patients with diabetes mellitus.

methodsThis study prospectively included 35 diabetic patients with stage C heart failure and 20 diabetic patients with or at risk of heart failure (stage A or B). Exhaled breath was collected after an overnight fast.

resultsThe stage C group had significantly higher brain natriuretic peptide levels, larger left ventricular diameter, lower left ventricular ejection fraction, and more frequent use of β-blocker, compared with the stage A or B group. The stage C group had higher exhaled acetone concentrations than the stage A or B group (p = 0.013). Exhaled acetone concentration was correlated with total ketone bodies (r = 0.588, p < 0.001) and brain natriuretic peptide (r = 0.415, p = 0.002).

conclusionStage C heart failure patients with diabetes mellitus have elevated exhaled acetone concentrations. Exhaled acetone concentration could be a noninvasive biomarker in heart failure patients with diabetes mellitus.

Indexed as

Breath TestsAcetoneAgedBiomarkersCross-Sectional StudiesDiabetes ComplicationsEchocardiographyFemaleHeart FailureHumansMaleMiddle AgedAcetoneBiomarkersAcetoneBreath analysisDiabetes mellitusHeart failure

Identifiers

PMID29145814
PMCPMC5689163
OpenAlexW2770041144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.